



Contact: Douglas A. Doerfler
President & CEO
MaxCyte, Inc.
(301) 517-5556
dougd@maxcyte.com

MAXCYTE AWARDED SBIR GRANT FOR DEVELOPMENT OF HIGH-SPEED CELL LOADING TECHNOLOGY – *STREAMING ELECTROPORATION*

MaxCyte advances leadership position in non-viral cell loading for therapeutics

Rockville, MD – August 12, 2003 – MaxCyte announced today that it received a Phase I award from the Small Business Innovation Research (SBIR) Program of the Department of Health and Human Services, National Institutes of Health (NIH) for its grant application *Development of a New Cell Loading System*. The SBIR award, the company's first, is designed to support research that demonstrates innovation and the potential for commercialization. The award will provide MaxCyte with up to \$96,000 of additional funding to develop its streaming electroporation system, a novel high-speed cell loading instrument for large volumes of cells.

With its current MaxCyte GT system, the company successfully overcame several problems of previous cell loading techniques, making it possible to increase throughput and cell viability so that the technology could go beyond research and development to support clinical applications. MaxCyte's project funded by the NIH produces the fastest cell loading procedure known to date, which can be scaled to any volume of biologic materials under sterile conditions. Application of this technology spans several high value areas including drug production, drug discovery in biotechnology, biodefense, agriculture and healthcare.

“Streaming technology significantly expands MaxCyte's capabilities beyond non-viral cell-based therapeutic products, serving to strengthen our leadership position in cell bading,” said Douglas A. Doerfler, MaxCyte president and CEO. “We successfully demonstrated to the NIH how our current cell loading system, the MaxCyte GT, routinely achieves efficiency and cell viability results that were unattainable in the past. This grant will allow us to expand the MaxCyte GT's applications to clinical autologous, allogeneic and industrial bioprocessing-scale cell loading.”

MaxCyte's Director of Research, Sergey Dzekunov, Ph.D. commented, “Cell loading is fundamental to biotechnology. We have developed an innovative technology that builds on the principle of our current platform by expanding the volume of materials to be loaded in a fraction of the time. This will enable our collaborators to achieve higher efficiencies at lower costs in a multitude of applications spanning from viral vector production to regenerative medicine.”

About MaxCyte

MaxCyte, Inc., a clinical stage biotechnology company, is commercializing the most efficient and non-viral cell loading technology available today. MaxCyte's pipeline includes one product in Phase I clinical trials for the treatment of Chronic Lymphocytic Leukemia and numerous late

stage preclinical therapeutic candidates in oncology, cardiopulmonary, autoimmune and genetic diseases. MaxCyte is enabling and improving non-viral therapeutic gene transfer, identifying more targeted ways to deliver drugs, and accelerating the drug discovery process. For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated.

###